ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Axitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor that was found to selectively inhibit the T315I-mutated BCR::ABL1 in CML and ALL through structural profiling and ex vivo characterization of drug sensitivity and resistance in patient cells [61].